These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 12392587)

  • 1. Direct in vivo evidence of a vascular statin: a single dose of cerivastatin rapidly increases vascular endothelial responsiveness in healthy normocholesterolaemic subjects.
    Omori H; Nagashima H; Tsurumi Y; Takagi A; Ishizuka N; Hagiwara N; Kawana M; Kasanuki H
    Br J Clin Pharmacol; 2002 Oct; 54(4):395-9. PubMed ID: 12392587
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Intense cholesterol lowering therapy with a HMG-CoA reductase inhibitor does not improve nitric oxide dependent endothelial function in type-2-diabetes--a multicenter, randomised, double-blind, three-arm placebo-controlled clinical trial.
    Balletshofer BM; Goebbel S; Rittig K; Enderle M; Schmölzer I; Wascher TC; Ferenc Pap A; Westermeier T; Petzinna D; Matthaei S; Häring HU
    Exp Clin Endocrinol Diabetes; 2005 Jun; 113(6):324-30. PubMed ID: 15977099
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cerivastatin, a hydroxymethylglutaryl coenzyme a reductase inhibitor, improves endothelial function in elderly diabetic patients within 3 days.
    Tsunekawa T; Hayashi T; Kano H; Sumi D; Matsui-Hirai H; Thakur NK; Egashira K; Iguchi A
    Circulation; 2001 Jul; 104(4):376-9. PubMed ID: 11468195
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Single administration of cerivastatin, an HMG-CoA reductase inhibitor, improves the coronary flow velocity reserve: a transthoracic Doppler echocardiography study.
    Takagi A; Tsurumi Y; Ishizuka N; Omori H; Arai K; Hagiwara N; Kasanuki H
    Heart Vessels; 2006 Sep; 21(5):298-301. PubMed ID: 17151817
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cerivastatin: a review of its pharmacological properties and therapeutic efficacy in the management of hypercholesterolaemia.
    Plosker GL; Dunn CI; Figgitt DP
    Drugs; 2000 Nov; 60(5):1179-206. PubMed ID: 11129127
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Both cerivastatin and fenofibrate improve arterial vasoreactivity in patients with combined hyperlipidaemia.
    Sebestjen M; Zegura B; Keber I
    J Intern Med; 2002 Jan; 251(1):77-85. PubMed ID: 11851868
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of statin versus fibrate on postprandial endothelial dysfunction: role of remnant-like particles.
    Wilmink HW; Twickler MB; Banga JD; Dallinga-Thie GM; Eeltink H; Erkelens DW; Rabelink TJ; Stroes ES
    Cardiovasc Res; 2001 Jun; 50(3):577-82. PubMed ID: 11376633
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Endothelial Effect of Statin Therapy at a High Dose Versus Low Dose Associated with Ezetimibe.
    Garcia MM; Varela CG; Silva PF; Lima PR; Góes PM; Rodrigues MG; Silva Mde L; Ladeia AM; Guimarães AC; Correia LC
    Arq Bras Cardiol; 2016 Apr; 106(4):279-88. PubMed ID: 27142792
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy and safety of cerivastatin, 0.2 mg and 0.4 mg, in patients with primary hypercholesterolaemia: a multinational, randomised, double-blind study. Cerivastatin Study Group.
    Ose L; Luurila O; Eriksson J; Olsson A; Lithell H; Widgren B
    Curr Med Res Opin; 1999; 15(3):228-40. PubMed ID: 10621930
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Atorvastatin restores endothelial function in normocholesterolemic smokers independent of changes in low-density lipoprotein.
    Beckman JA; Liao JK; Hurley S; Garrett LA; Chui D; Mitra D; Creager MA
    Circ Res; 2004 Jul; 95(2):217-23. PubMed ID: 15178637
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Influence of coenzyme Q(10) and cerivastatin on the flow-mediated vasodilation of the brachial artery: results of the ENDOTACT study.
    Kuettner A; Pieper A; Koch J; Enzmann F; Schroeder S
    Int J Cardiol; 2005 Feb; 98(3):413-9. PubMed ID: 15708173
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Oxidized-LDL levels are changed during short-term serum glucose variations and lowered with statin treatment in early Type 2 diabetes: a study of endothelial function and microalbuminuria.
    Paniagua JA; López-Miranda J; Pérez-Martínez P; Marín C; Vida JM; Fuentes F; Fernández de la Puebla RA; Pérez-Jiménez F
    Diabet Med; 2005 Dec; 22(12):1647-56. PubMed ID: 16401307
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Lipid-independent effects of statins on endothelial function and bioavailability of nitric oxide in hypercholesterolemic patients.
    John S; Schneider MP; Delles C; Jacobi J; Schmieder RE
    Am Heart J; 2005 Mar; 149(3):473. PubMed ID: 15864218
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of intensive lipid-lowering treatment compared to moderate lipid-lowering treatment with rosuvastatin on endothelial function in high risk patients.
    Egede R; Jensen LO; Hansen HS; Antonsen L; Hansen KN; Junker A; Thayssen P
    Int J Cardiol; 2012 Jul; 158(3):376-9. PubMed ID: 21349594
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacodynamics, safety, tolerability, and pharmacokinetics of the 0.8-mg dose of cerivastatin in patients with primary hypercholesterolemia.
    Stein E; Isaacsohn J; Stoltz R; Mazzu A; Liu MC; Lane C; Heller AH
    Am J Cardiol; 1999 May; 83(10):1433-6. PubMed ID: 10335757
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The effect of cerivastatin therapy on vascular responses to endothelin antagonists in humans.
    Leslie SJ; Spratt JC; Grieg L; Attina T; Denvir MA; Webb DJ
    J Cardiovasc Pharmacol; 2004 Nov; 44 Suppl 1():S410-2. PubMed ID: 15838335
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cerivastatin: pharmacology of a novel synthetic and highly active HMG-CoA reductase inhibitor.
    Bischoff H; Angerbauer R; Bender J; Bischoff E; Faggiotto A; Petzinna D; Pfitzner J; Porter MC; Schmidt D; Thomas G
    Atherosclerosis; 1997 Nov; 135(1):119-30. PubMed ID: 9395280
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Short-term therapy with relatively low-dose cerivastatin improves endothelial function independently of its lipid-lowering effect: Evaluation of brachial artery vasodilatation using B-mode ultrasound imaging.
    Sakabe K; Fukuda N; Nada T; Onose Y; Soeki T; Shinohara H; Tamura Y
    J Med Ultrason (2001); 2002 Dec; 29(4):225-30. PubMed ID: 27277967
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Endothelial nitric oxide synthase is essential for the HMG-CoA reductase inhibitor cerivastatin to promote collateral growth in response to ischemia.
    Sata M; Nishimatsu H; Suzuki E; Sugiura S; Yoshizumi M; Ouchi Y; Hirata Y; Nagai R
    FASEB J; 2001 Nov; 15(13):2530-2. PubMed ID: 11641268
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Differential in vitro response of the human radial artery versus left internal thoracic artery to cerivastatin: implications to bypass grafting.
    Nakamura K; Al-Ruzzeh S; Chester AH; Ilsley C; Yacoub MH; Amrani M
    Ann Thorac Surg; 2003 Dec; 76(6):2023-8. PubMed ID: 14667634
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.